Global Obsessive Compulsive Disorder Treatment Market Report and Forecast 2024-2032

Global Obsessive Compulsive Disorder Treatment Market Outlook

The global obsessive-compulsive disorders treatment market size attained a value of USD 508.62 million in 2023, driven by the increasing prevalence of the disorder and higher adoption of OCD medications in the high-income countries. The market is anticipated to grow at a CAGR of 9.1% during the forecast period of 2024-2032 to attain a value of USD 1,113.83 million by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Obsessive Compulsive Disorder treatment Insights

Obsessive compulsive disorder treatment (OCD) is a chronic mental illness characterised by obsessions, compulsions, or both. Obsessions or persistent unwanted ideas that induce a strong want to repeat a certain behaviour are common in people with OCD. The person then acts out that impulse, or compulsion, in order to alleviate the obsessive thought.

Obsessions and compulsions are the two main categories of symptoms associated with OCD. Many people who have OCD have both obsessions and compulsions, but some only have one or the other.

These symptoms do not just pass through. Even lesser symptoms can consume at least an hour of your time each day and have a substantial impact on your daily activities.

Obsessions or compulsions may impair a person’s ability to concentrate on work or finish responsibilities. They may even prevent you from attending school, work, or anywhere else.

A few common obsessions in OCD include contamination obsessions, sexual obsessions, violent obsessions, religious/moral obsessions, perfectionism obsessions, responsibility obsessions, identity obsessions, among others.

Common compulsions in OCD include washing and cleaning, mental compulsions, checking, and repeating, among others.

The disorder has also been connected to abnormal brain development and impairment in particular parts of the brain. Some data suggest that OCD is related to how the brain responds to serotonin. Serotonin is a neurotransmitter that regulates mood and sleep, among many other functions in the body.

Risk Factors for OCD

Trauma or Stress: Significant stress at home, school, job, or in personal relationships can increase your risk of developing OCD or exacerbate existing symptoms. 

Childhood maltreatment: Children who have experienced abuse or other traumatic childhood experiences, such as bullying or severe neglect, are more likely to acquire the illness.

Acute Neuropsychiatric Symptoms in Childhood (CANS): Some children develop OCD as a result of an infection. This illness is recognised as PANDAS after a streptococcal infection. PANDAS stands for paediatric autoimmune neuropsychiatric disorders associated with streptococcus. Symptoms can be caused by different infections or disorders.

TBI (Traumatic Brain Injury): A head injury is one of the primary symptoms of the disorder.

Diagnosis for OCD

The following steps may be taken to assist in the diagnosis of obsessive compulsive disorder treatment :

Psychological Assessment: The doctor talks about the thoughts, feelings, symptoms, and behavioural patterns to see if the person has obsessive or compulsive habits that are interfering with the quality of life.

OCD Diagnostic Criteria: The doctor may use criteria from the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-5).

Physical Examination: May be done to rule out any issues that could be causing your symptoms and to look for any complications.

According to the global congenital adrenal hyperplasia treatment market research report, the market can be categorised into the following segments: 

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Age Group

• Adults

• Pediatrics

• Others

Market Breakup by Therapy Type

• Cognitive Behavioural Therapy

• Augmentation Therapy

• Aversion Therapy

• Systematic Desensitization

• Others

Market Breakup by Severity

• Mild

• Moderate

• Severe

• Others

Market Breakup by Therapeutic Channel

• Public

• Private

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Obsessive Compulsive Disorder Treatment Epidemiology

OCD affects approximately 2.3% of the population or roughly one in every 40 adults and one in every 100 children in the United States. Females (1.8%) have a higher prevalence of OCD than males (0.5%). There is a 25% possibility that another direct family member will acquire symptoms in households with a history of OCD. 

The average age at which OCD symptoms start showing is 19.5 years. Males account for the vast majority of cases with relatively early onset. Almost a 5th of the male shows symptoms before the age of 10. Majority of girls are diagnosed with OCD throughout their youth (after age 10). People who develop OCD at a young age have more severe symptoms and greater incidences of ADHD and bipolar disorder.

Global Obsessive Compulsive Disorder Market Trends

One of the primary factors driving growth in the market for OCD drugs is the rising prevalence of the disorder. OCD is a severe mental condition that can endure for years. OCD is increasingly widespread in high-income countries due to a dramatic shift in people's lifestyles.

Throughout the forecast period, North America will account for the majority of market growth. In North America, drugs for obsessive compulsive disorder treatment are predominantly available in the United States and Canada. This region's market will grow faster than those in the rest of the world. The increased prevalence of OCD, government actions to combat OCD, and the availability of drugs would all contribute to the growth of the obsessive compulsive disorder pharmaceuticals market in North America over the forecast period.

Emerging Therapies

The US Food and Drug Administration approved the Ceruvia Lifesciences' Investigational New Drug (IND) Application for a Phase II clinical trial using synthetic psilocybin (SYNP-101) to treat obsessive compulsive disorder treatment (OCD) (FDA).

Numerous glutamatergic drugs are being studied. Medications that modulate the immune system and the inflammatory response are also being researched, and preliminary results are promising. Neurostimulation modalities are also being developed; preliminary evidence supports TMS, and the recent FDA clearance of TMS as an adjuvant for OCD will almost certainly lead to an increase in clinical use. 

Invasive surgical approaches, like as DBS and ablative operations, remain an option for treatment-refractory patients who have exhausted all other alternatives. Finally, in OCD, medicines with novel mechanisms of action and supplementary therapy methods are being researched.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the global obsessive compulsive disorder market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows: 

• Sun Pharmaceutical Industries Ltd.

• H. Lundbeck A/S

• Teva Pharmaceuticals USA, Inc.

• Elli Lilly & Company

• Apotex Inc.

• Viatris Inc.

• Lannett

• GlaxoSmithKline Plc

• F. Hoffmann-La Roche Ltd

• Pfizer Inc.

Key Highlights of the Report